Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 4/20 | 0.60 |
| ▸ | SRC | P12931 | 4/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28972615 | 0.89 | RAB9A (0.66) | RAB9ASMN1; SMN2NPC1LMNAKDM4E | |
| SCHEMBL28734870 | 0.81 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1LMNAKDM4E | |
| SCHEMBL28734841 | 0.79 | RAB9A (0.57) | RAB9ASMN1; SMN2NPC1LMNAKDM4E | |
| SCHEMBL28734871 | 0.78 | LMNA (0.55) | RAB9ASMN1; SMN2NPC1LMNAKDM4E | |
| SCHEMBL28734855 | 0.78 | ABL1 (0.52) | RAB9ASMN1; SMN2NPC1LMNAKDM4E | |
| SCHEMBL3467177 | 0.76 | RAB9A (0.64) | RAB9ASMN1; SMN2NPC1LMNAKDM4E | |
| SCHEMBL28413055 | 0.76 | RAB9A (0.67) | RAB9ASMN1; SMN2NPC1ALDH1A1ABL1 | |
| SCHEMBL3901791 | 0.76 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1LMNAALDH1A1 | |
| SCHEMBL15045105 | 0.72 | LMNA (0.69) | RAB9ASMN1; SMN2NPC1LMNAKDM4E | |
| SCHEMBL8779366 | 0.71 | ABL1 (0.84) | RAB9ASMN1; SMN2NPC1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | CDA, DCTD, ADA | RAB9A 2645/4885SMN1; SMN2 2561/4885NPC1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.